Piccotti Joseph R, LaGattuta Mark S, Knight Stephanie A, Gonzales Andrea J, Bleavins Michael R
Worldwide Safety Sciences, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA.
Drug Chem Toxicol. 2005;28(1):117-33. doi: 10.1081/dct-39743.
Phospholipidosis is the excessive accumulation of intracellular phospholipids in cell lysosomes. Drugs that induce this disease often share common physiochemical properties and are collectively classified as cationic amphiphilic drugs (CADs). Although the cause of phospholipidosis and morphologic appearance of affected lysosomes have been studied extensively, less is known about the physiologic effects of the condition. In the current study, U-937 cells were incubated with the CADs amiodarone (2.5-10 microg/mL) and imipramine (2.5-20 microg/mL). Treatment of U-937 cells with these compounds for 96 h resulted in concentration-related increases in phospholipids, as assessed by flow cytometry using the fluorophore nile red. These results were verified by measuring the concentrations of choline-derived phospholipids, which were significantly increased in drug-treated cells. Cell number in amiodarone (10 microg/mL) and imipramine (20 microg/mL) cultures following the 96-h incubation period were markedly reduced compared to control cultures. These observations suggested that accumulation of cellular phospholipids could inhibit cell proliferation. Flow cytometric analysis revealed a decrease in the percentage of cells in the S-phase of the cell cycle following drug treatment, yet DNA replication still occurred in a significant portion of cells. Interestingly, amiodarone and imipramine induced apoptosis in U-937 cells as shown by annexin V-FITC staining and DNA fragmentation. Enzymatic assays demonstrated that amiodarone and imipramine induced the activity of caspases 2 and 3. These results suggest that disruption of cell lysosomes in U-937 cells following accumulation of phospholipids does not cause a cell cycle arrest but instead induces apoptosis by activation of caspase pathways.
磷脂沉积症是细胞溶酶体内细胞内磷脂的过度积累。诱发这种疾病的药物通常具有共同的物理化学性质,被统称为阳离子两亲性药物(CADs)。尽管对磷脂沉积症的病因和受影响溶酶体的形态外观进行了广泛研究,但对该病症的生理影响了解较少。在当前研究中,将U - 937细胞与CADs胺碘酮(2.5 - 10微克/毫升)和丙咪嗪(2.5 - 20微克/毫升)一起孵育。用这些化合物处理U - 937细胞96小时导致磷脂浓度呈浓度相关增加,这通过使用荧光团尼罗红的流式细胞术评估得出。通过测量胆碱衍生磷脂的浓度验证了这些结果,在药物处理的细胞中其浓度显著增加。与对照培养物相比,在96小时孵育期后,胺碘酮(10微克/毫升)和丙咪嗪(20微克/毫升)培养物中的细胞数量明显减少。这些观察结果表明细胞磷脂的积累可能抑制细胞增殖。流式细胞术分析显示药物处理后细胞周期S期细胞百分比降低,但仍有相当一部分细胞发生DNA复制。有趣的是,如膜联蛋白V - FITC染色和DNA片段化所示,胺碘酮和丙咪嗪诱导U - 937细胞凋亡。酶活性测定表明胺碘酮和丙咪嗪诱导了半胱天冬酶2和3的活性。这些结果表明,U - 937细胞中磷脂积累后细胞溶酶体的破坏不会导致细胞周期停滞,而是通过激活半胱天冬酶途径诱导凋亡。